In total, 57.0% of hemorrhagic stroke patients had third-degree primary arterial hypertension (Table 1) and were discharged on angiotensin-converting enzyme inhibitors (71.3%), calcium channel blockers (60.7%), the diuretic, antihypertensive drug class (41.3%), angiotensin II receptor blockers (14.0%), or alpha 2 receptor blockers (19.4%) (Table 5). This evidence concerns the gene ACE and hemorrhagic stroke.